Siva Therapeutics, Inc.

Siva Therapeutics, Inc. is a biotechnology startup based in the United States specializing in developing innovative cancer therapies. Founded in 2010, the company's mission is to revolutionize cancer treatments by offering therapies that are less invasive, safer, more effective, less costly, and practical.

Their flagship product, Targeted Hyperthermia™, utilizes a photothermal device cancer therapy which leverages heat to irreversibly damage solid tumor tissue. This is achieved through the use of gold nanorods called SivaRods™, which absorb and re-emit infrared light as heat, targeting the leaky vasculature of solid tumors. The selectivity of tumor tissue's thermal sensitivity enables the therapy to deliver clean margins, promising extremely safe, effective, and cost-competitive results compared to traditional treatments such as surgery, chemotherapy, and radiation.

At the core of their development is the aim to address the current shortcomings of cancer treatments, which are often invasive, risky, disfiguring, moderately effective, and costly. Siva Therapeutics, Inc. seeks to offer a groundbreaking alternative through their innovative approach to cancer therapy.

The startup raised a significant $1.70M in its last Venture Round investment on 26 August 2017. The company's dedication to advancing cancer treatment in a more effective and less invasive manner has drawn attention from investors, positioning it as a noteworthy player in the field of oncology innovation.